CAJ | 학술논문

目的：探讨丙戊酸镁缓释片联合齐拉西酮治疗双相障碍躁狂发作的疗效和安全性。方法将76例双相障碍躁狂发作患者随机分为两组，均口服丙戊酸镁缓释片治疗，研究组联合齐拉西酮治疗，对照组联合利培酮治疗，观察6周。采用Bech-Rafaelsen躁狂量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组Bech-Rafaelsen躁狂量表评分均较治疗前显著下降（ P＜0．01），治疗6周末研究组痊愈率52．6％，总有效率84．2％，对照组分别为47．4％、86．8％，两组比较差异无显著性（χ2＝0．21、0．21，P＞0．05）。两组不良反应均轻微，但研究组月经改变、泌乳、体质量增加发生率显著低于对照组（P＜0．05）。结论丙戊酸镁缓释片联合齐拉西酮治疗双相障碍躁狂发作疗效显著，几乎不引起体质量增加、泌乳、月经改变，安全性高，依从性好，更适用于女性患者。
목적：탐토병무산미완석편연합제랍서동치료쌍상장애조광발작적료효화안전성。방법장76례쌍상장애조광발작환자수궤분위량조，균구복병무산미완석편치료，연구조연합제랍서동치료，대조조연합리배동치료，관찰6주。채용Bech-Rafaelsen조광량표평정림상료효，부반응량표평정불량반응。결과치료후량조Bech-Rafaelsen조광량표평분균교치료전현저하강（ P＜0．01），치료6주말연구조전유솔52．6％，총유효솔84．2％，대조조분별위47．4％、86．8％，량조비교차이무현저성（χ2＝0．21、0．21，P＞0．05）。량조불량반응균경미，단연구조월경개변、비유、체질량증가발생솔현저저우대조조（P＜0．05）。결론병무산미완석편연합제랍서동치료쌍상장애조광발작료효현저，궤호불인기체질량증가、비유、월경개변，안전성고，의종성호，경괄용우녀성환자。
Objective To explore the efficacy and safety of magnesium valproate sustained-release tablets (M VSRT ) plus ziprasidone in the treatment of manic episode of bipolar disorder .Methods Seventy-six patients with bipolar mania patients were randomly divided into two groups ,both groups took orally MVS-RT ,research group was plus ziprasidone ,and control group plus risperidone for 6 weeks .Efficacies were assessed with the Bech-Rafaelsen Mania Rating Scale (BRMS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the BRMS scores of both groups lowered more significantly compared with pretreatment (P<0 .01) ,at the end of the 6th week cure and total effec-tive rate were respectively 52 .6% and 84 .2% in research and 47 .4% and 86 .8% in control group ,which showed no significant group differences (χ2 = 0 .21 ,0 .21 ,P> 0 .05) .Adverse reactions of both groups were mild ,but the incidences of menstrual change ,lactation and weight gain were significant lower in re-search than control group (P<0 .05) .Conclusion MVSRT plus ziprasidone has an evident effect ,almost don’t cause weight gain ,lactation and menstrual change ,has higher safety and better compliance in the treatment of manic episode of bipolar disorder ,and are more suitable for female patients .